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A stability-indicating high-performance liquid chromatographic (HPLC) method was developed with 
short run time and validated for the assay of process related impurities of pantoprazole in bulk form. 
Resolution of drug, its potential impurities and degradation products were achieved on a Hypersil 
ODS column utilizing a gradient with 0.01 M phosphate buffer of pH 7 and acetonitrile as eluent, at 
the detection wavelength of 290 nm. Flow rate was set at 1 mL min-1. The procedure was found to be 
specific, linear (r=0.999), recovery (97.9-103%), LOD (0.043-0.047 µgmL-1), LOQ (0.13-0.14 µgmL-1) 
and robust. Acceptable robustness indicates that the assay method remains unaffected by small but 
deliberate variations. Pantoprazole was found to degrade in acidic, oxidative and under photolytic stress 
conditions. The drug was stable to alkaline and dry heat conditions. This method has been successively 
applied to pharmaceutical formulation and no interference from the excipients was found.
Uniterms: High performance liquid chromatography/qualitative analysis. High performance liquid 
chromatography/method development. Pantoprazole/forced degradation.
Desenvolveu-se método indicador de estabilidade por Cromatografia a Líquido de Alta Eficiência (CLAE) 
com pequeno tempo de corrida e validado para o ensaio de impurezas relacionadas ao processo de 
produção de pantoprazol em batelada. A determinação do fármaco, de suas impurezas potenciais e dos 
produtos de degradação foi realizada com coluna de ODS Hypersil, utilizando gradiente com tampão 
de fosfato 0,01 M pH 7 e acetonitrila como eluente, no comprimento de onda de detecção de 290 nm. A 
velocidade de fluxo foi fixada em 1 mLmin-1. O procedimento se mostrou específico, linear (r=0,999), 
com recuperação (97,9-103%), LOD (0,043-0,047 mgmL-1), LOQ (0,13-0,14 mg mL-1) e robusto. Robustez 
aceitável indica que o método de ensaio não é afetado por variações pequenas, exceto as planejadas. O 
pantoprazole degradou em condições ácidas, oxidativas e sob condições de estresse fotolítico. O fármaco 
foi estável em condições alcalinas e de calor seco. Este método tem sido sucessivamente aplicado à 
formulação farmacêutica e não se encontrou interferência de excipientes.
Unitermos: Cromatografia Líquido de Alta Eficiência/análise qualitativa. Cromatografia Líquido de 
Alta Eficiência/desenvolvimento de método. Pantoprazol/degradação forçada.
INTRODUCTION
[(Pyridylmethyl)sulfinyl]benzimidazoles (PSBs) 
have proved to be highly active inhibitors of the gastric 
(H+, K+)-ATPase both in vitro and in vivo with high and 
long lasting antisecretory activity (Wallmark et al.,1985; 
Larsson et al.,1983). Pantoprazole (PNT), 5-(difluo-
romethoxy)-2-[[(3,4- dimethoxy-2-pyridinyl)methyl]
sulfinyl]-1H-benzimidazole is an oral pharmaceutically 
active compound having promising anti-ulcer activity 
(Kohl et al., 1992) and belongs to the class of 2-[[(2- 
pyridyl) methyl]sulfinyl]-1H-benzimidazoles. In general 
these classes of compounds were used for the prevention 
and treatment of gastric acid related diseases (Kohl et al., 
1988). Literature studies reveal different methods for the 
preparation of PNT (Kormer et al., 1990).
Numerous methods have been developed for the 
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determination of PNT in the bulk drug substance or dos-
age forms, either alone or in the presence of other drugs. 
Techniques used for its assay include spectrophotometry 
(Moustafa et al., 2000; Wahbi et al., 2002; Rajic et al., 
2003; Salama et al., 2003; Rahman et al., 2005, 2006), 
polarography (Radi, 2003; Radi et al., 2003), thermogra-
vimetry (Reddy et al., 2007), amperometry (Castro et al., 
2005), HPLC (Mansour et al., 2000; Storms et al., 2002; 
Sivkumar et al., 2007, 2008; Margues et al., 2007; Patel 
et al., 2007; Zeinab et al., 2006), GC method (Nanduri et 
al., 2008), TLC (Agbaba et al., 2004; Gosavi et al. 2006), 
and capillary electrophoresis (Tivesten et al., 1999).
The presence of impurities in an active pharmaceuti-
cal ingredient (API) can have a significant impact on the 
quality and safety of the drug products. The regulatory 
framework basically addresses the development of analyti-
cal approaches focused on the impurities contained in the 
drugs. The requirements for testing the impurities become 
increasingly more complex due to the fact that the sources 
of potential impurities are numerous, including diverse 
synthetic routes, possible side reactions, degradation re-
actions affected by different storage conditions, different 
package materials, etc.
P N T i s  s y n t h e s i z e d  b y  c o n d e n s a t i o n  o f 
5-(difluoromethoxy)-2-mercapto-1H-benzimidazole 
(I) and 2-(chloromethyl)-3,4-dimethoxypiridine hydro-
chloride in the presence of an inorganic base, to yield 
5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl) 
methyl] thio-1H-benzimidazole (II), which—upon further 
oxidation with a suitable oxidizing agent eventually leads 
to pantoprazole. The route of synthesis and Chemical 
structures of the possible impurities contained in PNT are 
shown in Figure 1. The most important and critical step 
is PNT oxidation. Consequently, as a potential byproduct 
the sulfone, i.e., 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-
2-pyridinyl) methyl] sulfonyl-1H-benzimidazole (III), 
could appear via a structurally labile overoxidated sulf-
oxide (Mathad et al., 2004).
Forced degradation studies of new drug substances 
and drug products are essential to help develop and demon-
strate specificity of stability-indicating methods and to de-
termine the degradation pathways and degradation products 
of the active ingredients. Procedures for the preparation of 
specific degradation products needed for method validation 
often emerge from these studies (Dan et al., 2002).
Developing a short run time stability-indicating 
HPLC method for PNT is very challenging because there 
are many PNT related compounds which have similar 
structures as PNT. In this paper, we report the shorter 
analysis time (in comparison to European Pharmacopoeia, 
2008; Jelena et al., 2010; Jing-yi et al., 2010) stability-
indicating HPLC method for the estimation of PNT and its 
related substances in the presence of degraded impurities, 
employed by forced degradation method.
MATERIAL AND METHODS
Material
Used Chemicals were obtained from the following 
suppliers: Dipotassium hydrogen phosphate, disodium 
hydrogen phosphate, orthophosphoric acid, sodium hy-
droxide, hydrochloric acid, hydrogen peroxide (30%w/v) 
from Qualigens, Mumbai, India and Acetonitrile (ACN) 
HPLC grade (S.D. fine Chemicals, Mumbai, India). PNT, 
Impurity A/ 5-(difluoromethoxy)-2-{[(4,5-dimethoxypyr-
idin-2-yl)methyl]sulfonyl}-1H-benzimidazole (Sulfone), 
Impurity-B/ 5-(difluoromethoxy)-2-{[(4,5-dimethoxypyr-
idin-2-yl)methyl]sulfanyl}-1H-benzimidazole (Sulfide), 
Impurity-C/ 5-(difluoromethoxy)-1H-benzimidazole-
2-thiol (DBT) was obtained from Laurel Pharma, Ban-
galore. The PNT formulations i.e. Pantosec 40 (tablet), 
Allpan 40 (tablet), Altopan- i.v. (injection) are procured 
from local drug stores. The deionized water (Mili Q, In 
house) was used throughout.
Methods
Instrumentation
A HPLC (Shimadzu, ClassVP HPLC, Japan) 
equipped with Dual Wavelength absorbance detector, 
pH Meter (744 from Metrohm), Analytical Balance (XS 
205 from Mettler Toledo), Ultrasonic Bath (RX106 SO-
NOREX), Photostability Chamber (Thermo lab), autopip-
pette (100 – 1000 μL from Eppendorf), Oven (VA1,VA3 
from SHEL LAB) were used.
Chromatographic conditions
Gradient elution of mobile phase comprising of 
Acetonitrile and 0.01M phosphate buffer (pH of 7 adjusted 
FIGURE 1 - Synthesis scheme of pantoprazole Sodium.
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with orthophosphoric acid) with flow rate of 1mL min-1 
was performed on Hypersil ODS (125x4.0 mm, 5 µm). 
The column temperature was maintained at 40 oC and the 
injection volume was 20 μL. Prior to injection of analyte, 
the column was equilibrated for 30-40 min with mobile 
phase. The eluents were monitored at 290 nm, data were 
acquired, stored and analysed with Class VP Chromato-
graphic Software.
Preparation of stock and system suitability solution
All samples and standards were diluted using HPLC 
grade ACN and 0.1M Sodium hydroxide in the ratio of 
50:50 (v/v). Separate stock Solutions were prepared by 
dissolving appropriate amounts of PNT and related im-
purities by sonication followed by filling to the volume 
with the same diluent.
A stock solution was prepared for PNT (460 μg mL-1) 
and each impurity (A, B, C) having final concentration of 
440 μg mL-1. Equal volume (2 mL) of impurity B & im-
purity C was mixed from their stock solutions and further 
diluted to 100 mL with diluent labeled as stock A. For 
preparation of stock B, 2 mL of PNT & impurity A was 
mixed from their stock solutions and diluted to 100 mL by 
same diluent. The stock A & B was used further in vali-
dation studies. System suitability solution was prepared 
by adding 1 mL of sulphone impurity (of concentration 
46 μg mL-1) into 23 mg of PNT and volume was made upto 
50 mL by using diluents.
Sample solution
Ten tablets (Pantosec40 and Allpan 40) were 
weighed individualy and then powdered. Powder aliquot 
equivalent to 46 mg pure pantoprazole was accurately 
weighed and transferred to a 100 mL volumetric flask. 
For Injection vial (Altopan- i.v.) containing 46 mg pure 
PNT was dissolved in diluent and after sonication for 10 
min volume was made upto 100 mL in volumetric flask.
Forced degradation of Pentaprazole API
In order to establish whether the analytical method 
and the assay were stability indicating, the PNT was 
stressed under various conditions to promote degrada-
tion. 23 mg PNT was allowed to hydrolyze in base (0.1 N 
NaOH), acid (0.05 N HCl) and hydrogen peroxide (0.01%) 
separately for 2 minutes. Further the acid degraded solu-
tion was neutralized by adding 5 mL of 0.05 M sodium 
hydroxide and alkaline degraded solution was neutralized 
by adding 5 mL of 1 N hydrochloric acid. The volume of 
all three samples was made up with diluent upto 50 mL. 
PNT was also studied for its thermal degradation at 80 oC 
for 1 h respectively. For photolytic degradation 500 mg 
of PNT was transferred into two separate loss on drying 
(LOD) bottle each. One LOD bottle was covered with lid 
and then with aluminium foil (dark control) and another 
LOD bottle (photolytic exposed sample) was placed as 
such into the photolytic chamber by covering with lid in 
such a way to get the minimum exposure of 2600 lux of 
uv light for 100 hours. 23 mg of dark control sample and 
photolytic exposed sample was weighed and diluted each 
to 50 mL volume with the diluent. Single injection of blank 
and PNT solution was injected of all degradation condi-
tions. The peak purity and % degradation of PNT peak 
in all the degradation conditions was checked by using 
following formula:
 
Method validation
The method validation was done by evaluating 
specificity, detection limit (LOD) and quantitation limit 
(LOQ), linearity, accuracy, repeatability and reproduce-
bility, robustness and system suitability of PNT with im-
purities in accordance with ICH guidelines (ICH, 2005). 
The system suitability study was performed before each 
validation study.
Specificity
Specificity is the ability to assess unequivocally 
the analyte in the presence of components, which may be 
expected to be present. The specificity of the method was 
demonstrated by injecting each process-related impurity 
spiked with PNT. For specifity, the PNT sample was spiked 
with impurities by using stock solution A and B.
System suitability
System suitability test was performed to evaluate the 
chromatographic parameters (capacity factor, number of 
theoretical plates, asymmetry of the peaks and resolution 
between two consecutive peaks) before each validation 
run. The system suitability criterion is resolution between 
PNT and impurity sulfone peaks.
Linearity
The linearity of an analytical procedure is its ability 
to obtain test results, which are directly proportional to the 
concentration of the analyte in the sample. The linearity 
of response was determined in triplicate for all three im-
purities and PNT in the range from 0.1 to 2 μg mL-1. The 
dilutions were prepared by using impurity stock solution 
A & B. Response factor for all known impurities against 
Pantoprazole was calculated from the following formula:
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Limit of detection and quantification
The limit of detection (LOD) of a compound is de-
fined as the lowest concentration that can be detected. The 
limit of quantification (LOQ) is the lowest concentration of 
a compound that can be quantified with acceptable preci-
sion and accuracy. For each impurity and PNT the linearity 
data was used to determine residual standard deviation (σ) 
and slope (S). The LOD and LOQ were calculated from the 
data using formula 3σ/S and 10 σ/S respectively.
Accuracy
The accuracy of an analytical procedure expresses 
the closeness of agreement between the value, which is 
accepted either as a conventional true value or an ac-
cepted reference value and the value found. The recovery, 
evaluated with the standard addition procedure at three 
concentrations in triplicate at QL level, 100 % and 200 % 
of target limit.
Precision (repeatability and reproducibility)
The precision of an analytical procedure expresses 
the closeness of agreement between a series of measure-
ments from multiple sampling of the same homogeneous 
sample under prescribed conditions. Precision maybe 
considered as a repeatability and reproducibility.
Repeatability expresses the precision under the same 
operating conditions over a short interval of time. Repeat-
ability of the method was studied by spiking impurities 
with PNT at 100 % specification level. The precision was 
examined by analyzing six replicates and the percentage 
relative standard deviation was calculated for the area and 
retention time of all the impurities and PNT to demonstrate 
repeatability. Reproducebility of the method was studied 
by spiking impurities with PNT at 100% specification level 
on different day.
Reproducibility is normally expressed as the lack of 
the influence on the test results of operational and envi-
ronmental variables of the analytical method. In order to 
demonstrate reproducibility of the method the precision 
experiment was repeated by using different laboratory, 
different instrument, and different column on another 
day. The percentage bias of result was calculated between 
original condition and changed condition.
Robustness
The robustness of an analytical procedure is the 
measure of its capacity to remain unaffected by small, but 
deliberate, variations in method parameters and provides 
an indication of its reliability during normal usage. The 
HPLC parameters were deliberately varied from normal 
procedural conditions including detector wavelength 
(±5 nm), column oven temperature (±5 ºC), the flow rate 
(±10%), pH of buffer solution (±0.2), gradient program 
(±2 %) to test the robustness of the method.
Solution stability
Chromatographic analyses typically are performed 
by using autosamplers and overnight runs. As such, it is 
important to verify that the sample is stable in the solution 
prescribed by the method for periods encompassing the 
expected analysis duration period. Stability of test solu-
tion at analyte concentration was studied by keeping the 
solution in tightly capped volumetric flask at room tem-
perature on a laboratory bench for 24 h. The purity of the 
test solution was checked for by calculating % difference 
in peak area for PNT peak in standard and sample solution 
was calculated upto 24 h interval.
RESULT AND DISCUSSION
Development and optimization of the HPLC 
method
Proper selection of the method depends upon 
the nature of the sample (ionic or ionisable or neutral 
molecule) its molecular weight and solubility. PNT and 
their related impurities dissolve in polar solvents thus 
RP-HPLC was selected to estimate them. To develop a 
rugged and suitable stability indicating HPLC method 
for the quantitative determination of PNT and their im-
purities, the chromatographic conditions were selected 
after testing the different parameters such as columns, 
diluents, buffer, buffer concentration, organic solvent 
for mobile phase and mobile phase composition, gradi-
ent condition, column temperature and other chromato-
graphic conditions.
UV spectra of all the compounds were studied by 
scanning them between 190 nm to 400 nm. The wave-
length maximum of PNT was found to be 204 nm and 
302 nm. Since UV cut-off commonly uses solvent is up 
to 210 nm, therefore wavelength maximum that could 
be taken into consideration is between 280-310 nm. The 
lmax of most of the impurity lies near to 290 nm. During 
the experiments, it has been observed that baseline stabil-
ity, mobile phase interference and noise level were more 
desirable at 290 nm than 302 nm. Moreover, the adequate 
detection and quantification limit were found for all the 
impurities and PNT at 290 nm therefore, 290 nm was final-
ized as common wavelength for detection.
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TABLE I - HPLC method development and optimization trials
Trials 1 2 3 4 5 6
Mobile Phase 
pH-7.0 NHP 
(with TEA), 
A. Water: 
ACN::50:50
0.01 M NHP
pH-7.0 
(with OPA), 
A. Buffer: 
ACN:: 50:50
0.01 M NHP
pH-7.6 
(with OPA), 
A. Buffer: 
ACN::70:30
0.01 M KHP, pH-7.6 (with OPA),
A. Buffer: ACN::80:20
B. ACN: Buffer:: 30:70
0.01 M KHP, pH-7 (with OPA),
A. Buffer: ACN::80:20
B. ACN: Buffer:: 30:70
0.01 M KHP,
pH-7 (with OPA).
A. Buffer: 100,
B. ACN:100
Gradient 
condition
Time 
(min)
0.01 15 0.01 15 0.01 15 0.01 05 10 15 20 25 0.01 05 10 15 20 25 0.01 10 15 20
%MP-A 100 100 100 100 100 100 80 80 55 55 80 80 90 90 55 55 90 90 80 20 80 80
%MP-B NIL NIL NIL 20 20 45 45 20 20 10 10 45 45 10 10 20 80 20 20
Gradient curve  Linear  Linear Linear Linear Linear Linear
Column
Phenomenex 
Luna C8 
(150x4.6) 
mm, 5 µm
Zorbax 
SB C8 
(150x4.6) 
mm, 5 µm
Zorbax 
SB C8 
(150x4.6) 
mm, 5 µm
Hypersil ODS 
(125x4.0) mm,5 µm
Hypersil ODS 
(125x4.0) mm,5 µm
Hypersil ODS 
(125x4.0) mm,5 µm
Diluent MP-A MP-A MP-A MP-A MP-A
MP-A:0.1M 
NaOH::50:50
Temp. & 
wavelength
25 °C & 
290 nm
25 °C &
290 nm
25 °C & 
290 nm
40°C & 290 nm 40 °C & 290 nm 40 °C & 290 nm
Observations and corrections to next trial
Trial No. 1
Base line is good but the retention of the sample in the column was too much, fronting, no resolution between the peaks, buffer should be used 
within 10mM to 50mM with slightly basic pH within the range of Pka value to elute the sample early, stable bond column is needed.
Trial No. 2 Column was changed to stable bonded C8, reduction in fronting, base line is good, no peak resolution, buffer used to stabilize the pH, peak 
elution is too early.
Trial No. 3 Base line is good, resolution between the sulfone and PNT peak is more than 2 but no peak resolution to others.
Trial No. 4 Baseline is good, column was changed to stable bonded C18, gradient flow is used to increase the resolution between the peaks but still no 
resolution between DBT and Sulfone.
Trial No. 5 Base line is good, peak resolution between DBT and Sulfone & PNT and sulfide are not good, gradient should be changed. 
Trial No. 6 No interference of any peak with the main peak and to each other, resolution between the sulfone and Pantoprazole peak is more than 2.
MP- Percentage mobile phase, NHP- Disodium hydrogen phosphate, KHP- Disodium hydrogen phosphate, OPA - Orthophosphoric acid, ACN- HPLC grade 
acetonitrile, TEA- triethylamine.
Our preliminary trials using different columns 
(Phenomenex Luna C8, Zorbax SB C8), different mobile 
phases consisting of water-acetonitrile and sodium phos-
phate buffer- acetonitrile using isocratic elution did not 
give good peak shape and resolution. For the impurities 
and PNT, retention times were found near dead point. 
Therefore, in such case gradient elution is preffered over 
isocratic. To obtain efficient gradient elution pattern, small 
linear gradient was employed for development. Several, 
permutations and combination of ACN-buffer and buffer-
ACN with varying PH have been scanned to finalize the 
components of mobile phase. It has been observed that 
ACN (mobile phase-A) and phosphate buffer adjusted to 
pH 7.0 with orthophosphoric acid (mobile phase-B) with 
gradient elution provide best peak shape and resolution. 
The diluent preffered is 0.1M sodium hydroxide: ACN 
(50:50). Hypersil ODS a C18 column is preferred over 
C8 column because of its hydrophobicity so that to rec-
tify retention problems. Table I includes all the trials for 
optimization of method.
Forced degradation studies
In forced degradation method pantoprazole sodium 
was found to degrade substantially under acidic, oxidative 
conditions while stable under alkaline, thermal condition 
and under photolytic conditions was miniscule (Table II). 
The major impurity under acidic and oxidative condition 
was Sulfide (RRT 1.63) and Sulfone (RRT 0.80) respec-
tively (Figure 2).
Method validation
PNT and its related impurities were well resolved 
with no interference from the blank and mobile phase. For 
all compounds the purity angle was found to be less than 
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purity threshold value. The value of relative retention time 
and purity data is listed in table II. The described method 
is linear in the range of 0.1 μg mL-1 to 2 μg mL-1 of each 
impurity, demonstrated acceptability of the method for 
the quantitative determination in that range. The rela-
tive response factor (RRF) of Impurity-A, Impurity-B, 
Impurity-C with respect to PNT was found to be 1.13, 
0.93 and 0.59 respectively. The value of linearity range, 
equation, corellation coefficient, LOD and LOQ for PNT 
and its related impurity are shown in Table III.
In the precision study, the percentage relative stan-
dard deviation (RSD) of six replicates was found less than 
0.13 % for retention time and 1.12 % for peak area of all 
the impurities and PNT, indicating good repeatability of 
the method. The results of the reproducibility study under 
a different set of conditions are also in the same order of 
magnitude. The percentage bias between two different 
sets of conditions for retention time and peak area was 
within ±1.29 and ±0.29 respectively for all the impurities 
and PNT, indicates that method is rugged for its intended 
use. The method showed excellent recovery (accuracy) at 
three different studied concentrations QL, 100 and 200 % 
of specification level for all the impurities. The mean re-
coveries of all the impurities and PNT were found to be in 
the acceptable range of 97.94 to 102.6 %. Table IV shows 
all the data related to accuracy and precision.
FIGURE 2- Typical chromatogram for A) PNT with impurities; B) Under acidic condition and C) Under oxidative condition.
TABLE II - Results of specificity and purity data
Name Relative Retention time
Peak 
purity
Purity 
threshold
Pantoprazole 1.00 0.957 4.685
Impurity-A 0.80 3.984 7.596
Impurity-B 1.66 9.961 18.879
Impurity-C 0.57 2.331 4.355
TABLE III - Linearity, LOD and LOQ results for PNT and related impurities
Compound
Linearity
LOD & LOQ 
(µg mL-1)Equation Range 
(µg mL-1)
Correlation 
coefficient
Response 
Factor
PNT Y=46517x-496 0.13-2 0.9994 1 0.043& 0.129
Impurity A Y=41112x+422 0.14-2 0.9997 1.13 0.046 &0.138
Impurity B Y=49906x+328 0.14-2 0.9991 0.93 0.047&0.140
Impurity C Y=78900x-1399 0.13-2 0.9996 0.59 0.045&0.134
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TABLE V - Robustness data
Robustness Parameter Relative retention Time Resolution % RSD (n=6)
Impurity-A Impurity-B Impurity-C
Control 0.80 1.66 0.57 4.92 2.30
Flow rate (–10%) 0.80 1.60 0.59 4.25 0.23
Flow rate (+10%) 0.79 1.65 0.56 4.36 1.21
Column Oven Temp. (-5 °C) 0.80 1.64 0.61 4.94 0.82
Column Oven Temp. (+5 °C) 0.75 1.64 0.57 4.96 1.22
pH Change (– 0.2 pH units) 0.84 1.59 0.59 4.72 2.89
pH Change (+ 0.2 pH units) 0.68 1.76 0.62 4.84 1.99
Gradient change (–2 % absolute) 0.86 1.55 0.55 4.73 1.58
Gradient change (+2 % absolute) 0.83 1.69 0.56 3.30 1.85
Wavelength (–5 nm) 0.86 1.60 0.56 5.21 0.15
Wavelength (+5 nm) 0.86 1.60 0.56 5.24 0.35
TABLE VI - Assay of pantoprazole and its main impurities in pharmaceuticals
Formulation
Amount, %±SD
PNT Impurity-A Impurity-B Impurity-C
Pantosec 40 (tablet) 99.04±0.98 0.094±0.58 0.021±0.93 0.11±0.83
Allpan 40 (tablet) 101.23±1.81 0.075±0.61 0.072±1.09 0.089±0.41
Altopan- i.v. (injection) 98.34±2.30 0.092±0.33 0.088±0.34 0.061±1.02
TABLE IV - Precision and Accuracy data
Compound
ART (Min) % RSD 
(n=6)
% Bias
APA % RSD 
(n=6)
% Bias
Average 
Accuracy±SD % RSDOC DC OC DC
PNT 8.11 8.12 0.11 0.12 18480516.73 18480519.12 1.09 0.00 102.6±0.81 0.81
Impurity-A 6.63 6.61 0.13 0.30 57466 57482.42 0.89 0.03 101.64±2.3 1.10
Impurity-B 13.15 13.32 0.7 1.29 25339.79 25414.21 0.91 0.29 103±1.93 1.88
Impurity-C 4.62 4.58 0.09 0.87 36404.28 36492.18 1.12 0.24 97.94±1.91 1.96
ART- Average retention time, APA- Average peak area, OC-Original condition, DC-Different condition
Under robustness study, all analytes were adequately 
resolved. The LOQ solution maintained a signal-to-noise 
ratio over 10 in all varied conditions. The acceptance cri-
terion for system suitability and relative retention times 
of all known impurities were checked for each of the fol-
lowing variable chromatographic conditions and passed. 
The peak resolution between PNT and sulfone impuritiy 
were all larger than 3 under each variation. The results 
are shown in table V. No significant change in the process 
related impurity and PNT was observed during solution 
stability experiments and all the test solution was found 
to be stable for at least 24 h.
The method is used to assay the commercial dosage 
forms that contain PNT. Satisfactory results were obtained 
and in a good agreement with the labeled amount (Table VI).
The proposed method has shorter retention time 
for pantoprazole (8.01 versus 11 min) and significantly 
higher resolution factors for all of the resolved compounds 
as compared with the official European pharmacopoeia 
procedure (European Pharmacopoeia, 2008). Also the 
overall elution time is almost less than EP procedure and 
Letica et al. method (Jelena et al., 2010), about 15 min. 
The detection and quantization limits are camparable to 
Letica et al. The proposed method could be used for the 
fast assay of pantoprazole and its impurities in the bulk 
drug substance, or in its dosage forms.
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CONCLUSION
The proposed stability indicating reversed-phase, 
gradient HPLC method on Shimadzu Hypersil ODS col-
umn have been developed and validated. The concomi-
tant quantitation provides significant decrease in sample 
preparation, elution time, solvent and drug waste over the 
separation methods of analysis. Moreover, the specificity 
procedure and forced degradation studies revealed that the 
potential impurities i.e. Impurity A, Impurity B, Impurity 
C do not interfere with the determination of pantoprazole 
in the bulk and pharmaceutical formulations. The proposed 
HPLC method is simple, accurate, precise, specific, rugged 
according to ICH guidelines.
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